ANZUP Cancer Trials Group

What ANZUP Cancer Trials Group does

ANZUP Cancer Trials Group Ltd is an Australian not-for-profit cooperative clinical trials group founded in 2008 and headquartered at the Health Translation Hub in Randwick, Sydney. The organisation develops and runs investigator-initiated clinical trials across five urogenital cancer types — prostate, bladder, kidney, testicular, and penile — operating through a multidisciplinary network of more than 2,700 healthcare professionals, researchers, and consumer representatives at 298 trial sites across Australia, New Zealand, and internationally. Since inception ANZUP has conducted 39 clinical trials enrolling over 10,000 patients, with practice-changing outputs including ENZA-p (combination therapy for high-risk advanced prostate cancer), UpFrontPSMA (radioligand therapy sequencing), KEYPAD (kidney cancer combination therapy), PCR-MIB (muscle-invasive bladder cancer), and the iTESTIS registry (2,500+ germ cell tumour participants).

The organisation's products span a clinical trials platform, seed and partnership research grants (Below the Belt Research Fund, ANZUP/PCFA Partnership Grant, Synchrony and Noel Castan Fellowships), fellowships and scholarships, patient education resources, the Annual Scientific Meeting, Idea Generation Workshops, and the Below the Belt Bulletin newsletter. Core technology is the investigator-driven trial methodology, coordinating clinical design through partner centres such as the NHMRC Clinical Trials Centre, The George Institute for Global Health, Peter MacCallum Cancer Centre's BACT, and Walter and Eliza Hall Institute.

Revenue is generated through a diversified mix: infrastructure funding from the Australian Government via Cancer Australia, philanthropic donations (with DGR status across all Australian states/territories and donee status in New Zealand), corporate partnerships with pharmaceutical companies including AbbVie, Astellas, AstraZeneca, Bayer, BMS, Eisai, J&J, MSD, Novartis, and Pfizer, and partnership grants such as the three-year ANZUP/PCFA arrangement. Patient access is distributed through the 298 trial site network, while engagement with healthcare professionals and community members is sustained via membership programmes (ANZUP Membership and Friends of ANZUP), the Consumer Advisory Panel, and event-driven touchpoints at ASM, ESMO, ASCO, and ASCO GU.

Name

ANZUP Cancer Trials Group

Legal name

ANZUP Cancer Trials Group Ltd

Website

https://anzup.org.au

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

ANZUP Cancer Trials Group is an Australian not-for-profit cooperative clinical trials group founded in 2008 that designs and runs investigator-initiated clinical trials for urogenital cancers (prostate, bladder, kidney, testicular, penile), coordinating a network of 2,700+ professionals and 298 trial sites across Australia, New Zealand, and internationally.

Ownership category

akta.pro rank

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Government Infrastructure Funding: ANZUP receives infrastructure funding from the Australian Government through Cancer Australia for core operations and clinical trial coordination.
2. Philanthropic Donations and Fundraising: Individual donations, bequests, major gifts, and community fundraising support ANZUP's clinical trials research. ANZUP is registered as a charity with Deductible Gift Recipient (DGR) status in all Australian states and territories and donee status in New Zealand.
3. Partnership Grants: Partnership grants such as ANZUP/PCFA Partnership Grant fuel advancements in prostate cancer research through collaborative funding arrangements with organisations like Prostate Cancer Foundation of Australia.
4. Corporate Partnerships: Corporate partnerships with pharmaceutical companies including AbbVie, Astellas, AstraZeneca, Bayer, BMS, Eisai, J&J, MSD, Novartis, Pfizer provide support and collaboration for clinical trials.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

ANZUP Cancer Trials Group designs, coordinates, and conducts investigator-initiated clinical trials for urogenital (below-the-belt) cancers including bladder, kidney, testicular, penile, and prostate cancers. The organisation operates a 2,700+ member multidisciplinary network across 298 trial sites in Australia, New Zealand, and internationally, with 39 clinical trials since 2008 and 10,000+ patients enrolled. As a registered charity with DGR status, it supplements government infrastructure funding through philanthropic donations and corporate partnerships.

Product overview

ANZUP Cancer Trials Group is a not-for-profit cancer research charity that operates a unified clinical trials platform focused on below-the-belt (urogenital) cancers. The core product is its clinical trials program conducting investigator-initiated research across five cancer types: bladder, kidney, testicular, penile, and prostate cancers. Key trial products include ENZA-p, PCR-MIB, KEYPAD, iTESTIS registry, UpFrontPSMA, and TheraP. The organization supports its research mission through complementary modules including the Below the Belt Research Fund (seed grants), ANZUP Study Coordinator Scholarship, ANZUP/PCFA Partnership Grant, Synchrony Fellowship, Noel Castan Fellowship, and Best of the Best Awards. Patient and community engagement is facilitated through the Friends of ANZUP program and ANZUP Membership. The group also produces educational resources on all five cancer types and hosts the Annual Scientific Meeting, Idea Generation Workshops, and the Below the Belt Bulletin newsletter. ANZUP does not develop or sell standalone software products; its offering is entirely focused on clinical research services.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trials Program ANZUP's core offering: investigator-initiated clinical trials for below-the-belt (urogenital) cancers including bladder, kidney, testicular, penile, and prostate cancers, providing patients access to new therapies and generating practice-changing evidence across 298 trial sites in Australia, New Zealand, and internationally.
• ANZUP Membership Membership program open to healthcare professionals and researchers working in cancer care or cancer research professionally, providing access to the multidisciplinary network and trial participation opportunities.
• Friends of ANZUP Program Community membership program providing patients, carers, and community members with access to latest news in prostate, penile, testicular, kidney and bladder cancer trials, and opportunities to raise awareness or funds.
• Below the Belt Research Fund Research grants programme supporting bold, innovative ideas with potential to transform the future of urogenital cancer care, particularly for early-stage research that may not attract government or industry funding.
• ANZUP/PCFA Partnership Grant Three-year partnership grant with Prostate Cancer Foundation of Australia (PCFA) to fuel advancements for those affected by prostate cancer, building on a long-standing relationship.
• Synchrony Fellowship Fellowship programme supporting researchers in urogenital cancer research, providing funding and mentoring opportunities.
• Noel Castan Fellowship Fellowship programme for clinical researchers in urogenital cancer, supporting early- and mid-career investigator development.
• ANZUP Study Coordinator Scholarship Scholarship programme supporting study coordinators engaged in clinical trials research, providing professional development opportunities.
• Below the Belt Cancer Education Patient education resources covering bladder, kidney, testicular, penile, and prostate cancers, including symptoms, diagnosis, treatment options, and survivorship information.
• iTESTIS Registry Clinical registry enrolling over 2,500 participants to advance understanding of Germ Cell Tumours, supporting translational research in testicular cancer.

Quantifiable outcome

• 96% five-year survival rate for prostate cancer patients
• +4 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

13 partnerships are on record, tiered core, major and minor.

• Prostate Cancer Foundation of Australia (PCFA)coreStrategic or Co-development PartnerThree-year partnership building on long-standing relationship to fuel advancements in prostate cancer research. Partnership grant supports investigator-initiated clinical trials.
• MovembermajorStrategic or Co-development PartnerPhilanthropic group supporting ANZUP's below the belt cancer research initiatives.
• EORTC (European Organisation for Research and Treatment of Cancer)majorTechnology or IntegrationInternational cancer cooperative trials group collaboration for cross-border clinical trial research in urogenital cancers.
• Alliance for Clinical Trials in OncologymajorTechnology or IntegrationInternational collaboration with US-based cancer research organisation for clinical trial development.
• NHMRC Clinical Trials Centre, University of SydneycoreStrategic or Co-development PartnerCoordinating centre providing statistical leadership and clinical trial design expertise for ANZUP trials.
• The George Institute for Global HealthcoreStrategic or Co-development PartnerCoordinating centre partnership supporting oncology clinical trial development and delivery with dedicated project development manager.
• Walter and Eliza Hall Institute (WEHI)majorStrategic or Co-development PartnerCoordinating centre and fellowship partnership including ANZUP/WEHI Joint Fellow Dr Nadia Hitchen.
• AbbVieminorGTM or Marketing PartnerPharmaceutical partner supporting ANZUP clinical trials.
• AstraZenecaminorGTM or Marketing PartnerPharmaceutical partner supporting ANZUP clinical trials.
• NovartisminorGTM or Marketing PartnerPharmaceutical partner supporting ANZUP clinical trials.
• PfizerminorGTM or Marketing PartnerPharmaceutical partner supporting ANZUP clinical trials.
• Peter MacCallum Cancer CentrecoreStrategic or Co-development PartnerCentre for Biostatistics and Clinical Trials (BACT) provides coordinating centre services for ANZUP trials.
• GI Cancer GroupmajorTechnology or IntegrationNational Australian cancer cooperative trials group collaboration.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Canadian Cancer Trials Group: Canada's national cooperative cancer trials group based at Queen's University, conducting investigator-initiated trials. Named by ANZUP as an international collaborative partner; nearly identical operational model.
• NRG Oncology: US National Cancer Institute-funded cooperative oncology group conducting multi-modality clinical trials. Comparable cooperative trials group model serving similar investigator and patient populations in oncology.
• SWOG Cancer Research Network: One of the oldest US NCI-sponsored cooperative oncology groups, running a broad portfolio of investigator-initiated cancer trials. Closely comparable cooperative trials group model to ANZUP.
• COGNO (Cooperative Trials Group for Neuro-Oncology): Australian Cancer Trials Group funded by Cancer Australia, running investigator-initiated trials in neuro-oncology. Same funding mechanism, governance model, and 'cooperative trials group' structure as ANZUP.
• ECOG-ACRIN Cancer Research Group: Large US cooperative group performing investigator-initiated cancer clinical trials with a similar member-network and coordinating-centre structure. Same category of organization as ANZUP but at larger US scale.
• Gastrointestinal Cancer Institute (GI Cancer Institute): Australian cooperative clinical trials group focused on GI cancers, also Cancer Australia-funded and named as an ANZUP collaborator. Near-identical operating model to ANZUP but in a different tumour vertical.
• Alliance for Clinical Trials in Oncology: US-based NCI-sponsored cooperative trials group running investigator-initiated oncology trials. ANZUP names Alliance as an active international partner, and the structural and funding model is closely analogous.
• EORTC (European Organisation for Research and Treatment of Cancer): Europe's leading cooperative cancer clinical trials group, running investigator-initiated trials across multiple tumour types. ANZUP explicitly partners with EORTC on cross-border GU cancer studies, making it the closest international analogue.
• Breast Cancer Trials: Australian and New Zealand cooperative breast cancer clinical trials group, sharing the ANZUP-style investigator-initiated model, Cancer Australia funding pathway, and member-network structure, focused on breast rather than GU cancers.

Broad incumbents

• Cancer Research UK: UK's largest cancer research charity, funding and coordinating a broad portfolio of cancer trials including investigator-initiated work. Larger, broader incumbent in the same clinical cancer research space as ANZUP.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Customer concentration

• Xx.com/ANZUPtrials
• Facebookfacebook.com/ANZUPtrials
• LinkedInau.linkedin.com/company/anzuptrials
• Instagraminstagram.com/anzuptrials

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ANZUP Cancer Trials Group